15
results
for author:"Gu T.-L."
in Literature Citations
| Phosphorylation of the SSBP2 and ABL proteins by the ZNF198-FGFR1 fusion kinase seen in atypical myeloproliferative disorders as revealed by phosphopeptide-specific MS. Kasyapa C., Gu T.L., Natarajan L., Polakiewicz R., Cowell J.K. Proteomics 9:3979-3988(2009) · Mapped (45) |
| Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Yu J., Kane S., Wu J., Benedettini E., Li D., Reeves C., Innocenti G., Wetzel R., Crosby K., Becker A. et al. Clin. Cancer Res. 15:3023-3028(2009) · Mapped (15) |
| Fibroblast growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformation. Kang S., Elf S., Dong S., Hitosugi T., Lythgoe K., Guo A., Ruan H., Lonial S., Khoury H.J., Williams I.R. et al. Mol. Cell. Biol. 29:2105-2117(2009) · Mapped (9) |
| Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. Tam W.F., Gu T.L., Chen J., Lee B.H., Bullinger L., Frohling S., Wang A., Monti S., Golub T.R., Gilliland D.G. Blood 112:1981-1992(2008) · Mapped (1) |
| Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and src-dependent tyrosine phosphorylation of RSK2 at Tyr-529. Kang S., Dong S., Guo A., Ruan H., Lonial S., Khoury H.J., Gu T.L., Chen J. J. Biol. Chem. 283:4652-4657(2008) · Mapped (11) |
| Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y. et al. Cell 131:1190-1203(2007) · UniProtKB (487) |
| FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Kang S., Dong S., Gu T.L., Guo A., Cohen M.S., Lonial S., Khoury H.J., Fabbro D., Gilliland D.G., Bergsagel P.L. et al. Cancer Cell 12:201-214(2007) · Mapped (10) |
| A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. Gu T.L., Mercher T., Tyner J.W., Goss V.L., Walters D.K., Cornejo M.G., Reeves C., Popova L., Lee K., Heinrich M.C. et al. Blood 110:323-333(2007) · Mapped (16) |
| Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles. Matheny C.J., Speck M.E., Cushing P.R., Zhou Y., Corpora T., Regan M., Newman M., Roudaia L., Speck C.L., Gu T.L. et al. EMBO J. 26:1163-1175(2007) · Mapped (7) |
| Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. Gu T.-L., Goss V.L., Reeves C., Popova L., Nardone J., Macneill J., Walters D.K., Wang Y., Rush J., Comb M.J. et al. Blood 108:4202-4204(2006) · UniProtKB (2) |
| Activating alleles of JAK3 in acute megakaryoblastic leukemia. Walters D.K., Mercher T., Gu T.L., O'Hare T., Tyner J.W., Loriaux M., Goss V.L., Lee K.A., Eide C.A., Wong M.J. et al. Cancer Cell 10:65-75(2006) · Mapped (6) |
| JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Mercher T., Wernig G., Moore S.A., Levine R.L., Gu T.L., Frohling S., Cullen D., Polakiewicz R.D., Bernard O.A., Boggon T.J. et al. Blood 108:2770-2779(2006) · Mapped (8) |
| NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. Gu T.L., Tothova Z., Scheijen B., Griffin J.D., Gilliland D.G., Sternberg D.W. Blood 103:4622-4629(2004) · Mapped (16) |
| Cbfa2 is required for the formation of intra-aortic hematopoietic clusters. North T., Gu T.L., Stacy T., Wang Q., Howard L., Binder M., Marin-Padilla M., Speck N.A. Development 126:2563-2575(1999) · Mapped (2) |
| The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Wang Q., Stacy T., Miller J.D., Lewis A.F., Gu T.L., Huang X., Bushweller J.H., Bories J.C., Alt F.W., Ryan G. et al. Cell 87:697-708(1996) · Mapped (4) |
